NDC codes

FDA NDC Directory
Product NDC (as listed)61919-827Labeler and product segments. Claims need a package NDC.
Product NDC at billing width61919-0827Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
61919-827-156191908271515 TABLET in 1 BOTTLE (61919-827-15)Marketed from Jun 15, 2020
61919-827-216191908272121 TABLET in 1 BOTTLE (61919-827-21)Marketed from Jun 15, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Dexamethasone
Generic name (nonproprietary)
dexamethasone
Active ingredients
Dexamethasone — 1.5 mg/1
Dosage form
Tablet
Route
Oral
Labeler
Direct Rx
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 084610
Marketing start
Listing expires
Other FDA classes
Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers
Product ID 61919-827_0e883a0f-ef16-109e-e063-6294a90aa908SPL ID 0e883a0f-ef16-109e-e063-6294a90aa908SPL set ID 3ff06262-4c6f-4423-99fa-b4d8191ea133RxCUI 197580UNII 7S5I7G3JQL
Pharmacologic class
Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N461919082715 followed by a unit qualifier and the quantity

Package 61919-0827-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

INDICATIONS AND USAGE SECTION Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineraloco…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in